Trials / Recruiting
RecruitingNCT05103683
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- TORL Biotherapeutics, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TORL-1-23 | antibody drug conjugate (ADC) |
Timeline
- Start date
- 2021-11-17
- Primary completion
- 2026-08-31
- Completion
- 2026-11-15
- First posted
- 2021-11-02
- Last updated
- 2026-02-13
Locations
14 sites across 2 countries: United States, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05103683. Inclusion in this directory is not an endorsement.